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Abstract: Background: Australian patients with chronic kidney disease (CKD) are routinely managed
in general practices with multiple medications. However, no nationally representative study has
evaluated the quality of prescribing in these patients. The objective of this study was to examine
the quality of prescribing in patients with CKD using nationally representative primary care data
obtained from the NPS MedicineWise’s dataset, MedicineInsight. Methods: A cross-sectional analysis
of general practice data for patients aged 18 years or older with CKD was performed from 1 February
2016 to 1 June 2016. The study examined the proportion of patients with CKD who met a set of 16
published indicators in two categories: (1) potentially appropriate prescribing of antihypertensives,
renin-angiotensin system (RAS) inhibitors, phosphate binders, and statins; and (2) potentially
inappropriate prescribing of nephrotoxic medications, such as non-steroidal anti-inflammatory drugs
(NSAIDs), at least two RAS inhibitors, triple therapy (an NSAID, a RAS inhibitor and a diuretic),
high-dose digoxin, and metformin. The proportion of patients meeting each quality indicator was
stratified using clinical and demographic characteristics. Results: A total of 44,259 patients (24,165
(54.6%) female; 25,562 (57.8%) estimated glomerular filtration (eGFR) 45–59 mL/1.73 m2) with CKD
stages 3–5 were included. Nearly one-third of patients had diabetes and were more likely to have their
blood pressure and albumin-to-creatinine ratio monitored than those without diabetes. Potentially
appropriate prescribing of antihypertensives was achieved in 79.9% of hypertensive patients with
CKD stages 4–5. The prescribing indicators for RAS inhibitors in patients with microalbuminuria
and diabetes and in patients with macroalbuminuria were achieved in 69.9% and 62.3% of patients,
respectively. Only 40.8% of patients with CKD and aged between 50 and 65 years were prescribed
statin therapy. The prescribing of a RAS inhibitor plus a diuretic was less commonly achieved, with
the indicator met in 20.6% for patients with microalbuminuria and diabetes and 20.4% for patients
with macroalbuminuria. Potentially inappropriate prescribing of NSAIDs, metformin, and at least
two RAS inhibitors were apparent in 14.3%, 14.1%, and 7.6%, respectively. Potentially inappropriate
prescribing tended to be more likely in patients aged ≥65 years, living in regional or remote areas,
or with socio-economic indexes for areas (SEIFA) score ≤ 3. Conclusions: We identified areas for
possible improvement in the prescribing of RAS inhibitors and statins, as well as deprescribing of
NSAIDs and metformin in Australian general practice patients with CKD.
Keywords: chronic kidney disease; drug therapy; quality indicators; appropriate prescribing; general
practice; quality use of medicine; primary care
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1. Background
In 2015, an estimated 1.7 million Australian adults aged 18 years or older had indicators of chronic
kidney disease (CKD), and of these, 604,000 had CKD stages 3–5 [1]. Diabetes and hypertension caused
up to two-thirds of CKD cases. Approximately one in three and three in four Australian general practice
patients with CKD had recorded diagnoses of diabetes and hypertension, respectively [2]. Progressive
kidney damage with hypertension and diabetes leads to end-stage kidney disease (ESKD) [3]. In 2016
alone, 2800 new cases of ESKD were reported in Australia [4]. Patients with ESKD require expensive
replacement therapy, and their treatment costs the Australian economy 1 billion per year [1].
Prevention of CKD progression is cost-effective and is most successful within primary care [3]. In
Australia, the majority of patients with CKD stages 3–5 receive treatment from general practices [2].
Prevention of CKD progression can be achieved by treatment of modifiable risk factors and avoidance of
nephrotoxic medication [3]. Kidney Health Australia’s ‘CKD management in general practice’ guideline
recommends, depending on the stage of CKD, adequate treatment of hypertension, dyslipidaemia,
and albuminuria [3]. It recommends controlling blood pressure at ≤140/90 mm Hg in patients with
CKD alone and ≤130/80 mm Hg in those comorbid with albuminuria or diabetes [3].
Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are
first-line antihypertensive agents in CKD patients with albuminuria or diabetes [3]. These classes of
drugs not only lower blood pressure but also decrease the progression of albuminuria [3]. Statin therapy
is recommended in patients with CKD and aged 50 years or older as it reduces cardiovascular risk
and progression of CKD [5,6]. Australian guidelines also recommend avoiding the use of medications
that can potentially damage kidney function or readily accumulate and cause toxicity [6]. These
medications include non-steroidal anti-inflammatory drugs (NSAID), metformin, and a high dose of
digoxin [3].
There is limited research investigating the quality of CKD care in Australian patients [7–10]. The
available studies have focused on specific classes of medications [8,9] and specific regions [7,9] or
single centres [10] that may not be generalisable to the broader CKD population in Australia. There
remains a need to assess prescribing quality with validated indicators in patients with CKD. Smits et al.
developed a set of 16 prescribing quality indicators (PQIs) [11], which were developed according to
international guidelines recommendations and are relevant to evaluate the quality of CKD care in a
primary care setting [12,13]. We aimed to evaluate the quality of Australian prescribing with these
indicators in patients with CKD using a large and nationally representative general practice dataset.
2. Methods
We analysed retrospective data obtained from the NPS MedicineWise MedicineInsight dataset.
The data were de-identified and extracted from the electronic health records (EHRs) of general practices
and included demographics, encounters, diagnoses, prescriptions, observations, and pathology tests.
NPS MedicineWise MedicineInsight is the largest geographically representative primary care dataset
in Australia. As of October 2018, NPS MedicineWise MedicineInsight had recruited 671 general
practices across Australia. A total of 2,974,031 included patients had at least three clinical encounters
in the previous two years. Details about this dataset can be found elsewhere [2,14–16]. We used
MedicineInsight data collected from 329 general practices between 1 January 2013 and 1 June 2016.
In this study, we included patients with evidence of CKD based on having two renal function
tests that were performed at least three months apart with: (1) estimated glomerular filtration rate
(eGFR) values <60 mL/min/1.73 m2 or (2) albumin-to-creatinine ratio (ACR) values ≥3.5 mg/mmol
for females or ≥2.5 mg/mmol for males. The renal function tests were performed between 1 January
2013 and 1 June 2015. The CKD epidemiology collaboration equation (CKD-EPI) was used to calculate
eGFR [17]. This definition of CKD is congruent with that recommended for the diagnosis of CKD in
Australian general practice [3]. Regular patients (defined by the Royal Australian College of General
Practitioners as those with three or more encounters in the previous two years) [16] were included,
if at the time of data extraction (July 2016) they were aged at least 18 years. Patients were excluded
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if they did not have at least one follow-up general practitioner (GP) visit between 2 June 2015 and
1 June 2016, in addition to patients who died during that period.
Variables such as age, gender, socio-economic status (based on the Index of Relative Socio-economic
Advantage and Disadvantage, one of the socio-economic indexes for areas (SEIFA)) [18], rurality,
continuity of care (CoC), documentation of a diagnosis of CKD, and serum electrolyte levels
(e.g., calcium, and phosphate) were examined. SEIFA quintile was an index developed by the
Australian Bureau of Statistics (ABS) and ranks areas in Australia from 1 (most disadvantaged area)
to 5 (most advantaged area) [18]. Rurality was assigned according to the postcode of the patient’s
residence and classified as major cities, regional, remote, and very remote Australia [19]. SEIFA quintile
was categorised into SEIFA ≤ 3 vs. SEIFA > 3 and rurality to major cities vs. regional and remote
Australia. CoC was calculated for each included patient after the time of laboratory evidence of CKD,
over the remainder of the data collection period, using the Herfindahl–Hirschman Index, which has
been shown to be highly correlated with other common measures of CoC [20]. Its value ranged from 0
to 1 and cut off points for low and high CoC were <0.75 and >=0.75, respectively. Low CoC in general
practice, measured with this index, has also been associated with a higher risk of mortality [21,22].
Documentation of a diagnosis of CKD was extracted from condition codes. Baseline comorbidities,
including myocardial infarction, hypertension, and diabetes were examined. The comorbidities
were based on ‘condition flags’ provided by MedicineInsight. The prescribed medications that were
examined included: diuretics (anatomical therapeutic chemical (ATC) code: C03), beta-blockers (C07),
calcium channel blockers (C08), ACEIs (C09A), ARBs (C09C), other agents acting on renin-angiotensin
system (RAS) (C09), other antihypertensives (C02), statins (C10AA or combinations as in C10BA and
C10BX), phosphate binders (A12AA04, A12AA12, V03AE, and A02AB01), erythropoiesis-stimulating
agents (ESAs) (B03XA), non-steroidal anti-inflammatory drugs (NSAIDs) (M01A, M01BA and B01AC),
metformin (A10BA02 or in combination as A10BD), and digoxin (C01AA05).
The recorded data included prescriptions and laboratory tests during the last four months of
follow-up (between 1 February 2016 and 1 June 2016). The 16 PQIs, developed and validated by
Smits et al. [11] in the Netherlands, were used to evaluate this data. They were categorised into two
domains: appropriate and inappropriate PQIs. Detailed definitions for all indicators are shown in
Table 4. The appropriate prescribing domain includes the first nine indicators that evaluate prescribing
of all antihypertensive agents in patients with hypertension, RAS inhibitors, or diuretics in patients
with proteinuria or diabetes, statins, and phosphate binders. The inappropriate prescribing domain
contains the remaining seven indicators that assess the prescribing of ESA in patients with CKD and
haemoglobin ≥7.5 g/dL, use of NSAIDs and metformin in patients with eGFR < 30 mL/min/1.73 m2,
high-dose digoxin in patients with eGFR <50 mL/min/1.73 m2, simultaneous use of at least two RAS
inhibitors, and triple therapy with an NSAID, RAS inhibitor, and diuretic. The use of phosphate binders
and ESAs was not captured in our dataset as nephrologists in Australia typically prescribe them.
Simultaneous prescribing of RAS blockers was defined as at least two of the ATC codes C09A,
C09B, C09C, C09D, C09X, or combination (as in C10BX) within the last four months of the follow-up
(between 1 February 2016 and 1 June 2016). Simultaneous use of NSAID, RAS blocker, and diuretic was
defined as at least one prescription for each of the three classes of medications during the follow-up
period. It was acknowledged that we were not capable of capturing the use of over-the-counter
NSAIDs. We could also not capture whether NSAIDs were prescribed as a regular medication or for
‘as needed’ use.
2.1. Statistical Analysis
Patient demographics and clinical characteristics were compared between patients with and
without diabetes and are presented as numbers and proportions. The proportion of patients who met
PQIs criteria are shown as percentages with 95% confidence intervals (CIs). We stratified the proportion
of patients meeting each indicator by gender, age, SEIFA, rurality, CKD diagnosis documentation, and
CoC. Chi-square tests were used to determine differences in the quality of prescribing with patient
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characteristics. All data analyses and management were conducted using the statistical and graphical
computing language of R [23]. A two-sided p value of less than 0.05 was considered to indicate
statistical significance.
2.2. Ethics Approval and Consent to Participate
Ethics approval was obtained from the Tasmanian Health and Medical Human Research Ethics
Committee (H0015651). De-identified data obtained from the MedicineInsight for this study did
not have any patient-specific information, such as date of birth, age and postcode and individual
patient consent was waived for our ethics application. Patients were informed about the programme
through promotional material that was displayed with the waiting room of all participating practices.
Patients choice to opt-out from the programme was respected, and robust and effective security controls
safeguarded their safety.
3. Results
3.1. Baseline Charactersitics
The cohort was composed of 44,259 patients with evidence of CKD. Of these, 24,165 (54.6%) were
females, and 70% were aged 70 years or older. Most patients (57.8%) had eGFR values between 45
and 59 mL/min/1.73 m2. Only a quarter of patients with evidence of CKD had documentation of
the diagnosis, and documentation was less likely with increasing age (e.g., 51.3% for patients aged
30–39 years with evidence of CKD vs. 23.9% in those aged ≥80 years; p < 0.001). The sociodemographic
and clinical characteristics of the study participants, including medications prescribed and monitoring
performed, are shown in Tables 1–3.
A total of 13,263 patients (30%) had diabetes. Of these, 11,608 (87.5%) and 6608 (87.5%) had
hypertension and a history of myocardial infarction, respectively (Table 2). Of 39,716 (89.7%) patients
who had a recorded blood pressure measurement, 13,338 (33.6%) had uncontrolled blood pressure
(>140/90 mm Hg). The proportion of patients with uncontrolled blood pressure was slightly higher in
patients with diabetes (34.4% vs. 33.2%, p = 0.03) than in those without diabetes. Antihypertensive
medication prescribing was significantly higher in CKD patients with diabetes compared with those
without diabetes (82.1% vs. 70.6%, p < 0.001). Compared with CKD patients without diabetes, CKD
patients with diabetes were more likely to be prescribed an ACEI/ARB (64.1% vs. 51.5%, p < 0.001).
Over 60% of CKD patients with diabetes were prescribed a statin compared with less than 40% without
diabetes (p < 0.001) (Table 3).
Only a few patients had recorded treatment with phosphate binders, ESAs, and vitamin D.
Therefore, the three PQIs: seven, eight, and nine that assess appropriate prescribing of phosphate
binders and the two PQIs: 11 and 12 that evaluate inappropriate prescribing of vitamin D and ESAs
were not operational. These five indicators were excluded from further analyses.
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Table 1. Baseline sociodemographic characteristics of patients with chronic kidney disease (CKD)
overall and by diabetes status.
Overall, n =
44,259 n (%)
Diabetes
p ValueNo n = 30,996
n (%)
Yes n = 13,263
n (%)
Age groups (years) <0.836
<65 4373 (9.9) 3069 (9.9) 1304 (9.8)
≥65 39,886 (90.1) 27,927 (90.1) 11,959 (90.2)
Female 24,165 (54.6) 17,620 (56.8) 6545 (49.3) <0.001
Indigenous Status <0.001
Indigenous 436 (1.0) 212 (0.7) 224 (1.7)
Non-Indigenous 33,067 (74.7) 23,020 (74.3) 10,047 (75.8)
Missing 10,756 (24.3) 7764 (25.0) 2992 (22.6)
SEIFA quintile *
≤3 12,254 (27.8) 8302 (26.9) 3952 (30.0) <0.001
>3 31,754 (72.2) 22,559 (73.1) 9225 (70.0)
Missing 251 (0.6) 165 (0.5) 86 (0.6)
Rurality * <0.001
Major Cities of Australia 26,617 (60.4) 18,468 (59.9) 8149 (61.8)
Regional and Remote Australia 17,420 (39.6) 12,385 (40.1) 5035 (38.2)
Missing 222 (0.5) 143 (0.5) 79 (0.6)
GP Continuity of Care <0.001
Low (<0.75) 17,421 (39.4) 11,917 (38.5) 5504 (41.5)
High (≥0.75) 26,833 (60.6) 19,075 (61.5) 7758 (58.5)
Missing 5 (0.0) 1 (0.0) 4 (0.0)
Documentation of CKD 11,618 (26.3) 7722 (24.9) 3896 (29.4) <0.001
SEIFA, socio-economic indexes for areas; GP, general practitioner. * Excludes patients without a recorded postcode
in the electronic health record.
Table 2. Comorbidities of patients with CKD overall and by diabetes status.
Overall, n =
44,259 n (%)
Diabetes
p ValueNo n = 30,996
n (%)
Yes n = 13,263
n (%)
CKD Stage <0.001
Stage 3a (45–59 mL/min/1.73 m2) 25,562 (57.8) 18,724 (60.4) 6838 (51.6)
Stage 3b (30–44 mL/min/1.73 m2) 13,551 (30.6) 9093 (29.3) 4458 (33.6)
Stage 4 (15–29 mL/min/1.73 m2) 4186 (9.5) 2573 (8.3) 1613 (12.2)
Stage 5 (<15 mL/min/1.73 m2) 960 (2.2) 606 (2.0) 354 (2.7)
ACR (mg/mmol) 0.023
Normal
<2.5 (male)
<3.5 (female)
7877 (17.8) 3838 (12.4) 4039 (30.5)
Microalbuminuria
2.5–25 (male)
3.5–35 (female)
4707 (10.6) 1719 (5.6) 2978 (22.5)
Macroalbuminuria
>25 (male)
>35 (female)
2427 (5.5) 897 (2.9) 1530 (11.5)
Missing 29,248 (66.1) 24,532 (79.1) 4716 (35.6)
Indigenous Status <0.001
Indigenous 436 (1.0) 212 (0.7) 224 (1.7)
Non-Indigenous 33,067 (74.7) 23,020 (74.3) 10,047 (75.8)
Missing 10,756 (24.3) 7764 (25.0) 2992 (22.6)
Comorbidities
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Table 2. Cont.
Overall, n =
44,259 n (%)
Diabetes
p ValueNo n = 30,996
n (%)
Yes n = 13,263
n (%)
Hypertension 35,386 (80.0) 23,778 (76.7) 11,608 (87.5) <0.001
Myocardial infarction 17,945 (40.5) 11,688 (37.7) 6257 (47.2) <0.001
Atrial fibrillation 7038 (15.9) 4893 (15.8) 2145 (16.2) 0.315
Anxiety 5658 (12.8) 4124 (13.3) 1534 (11.6) <0.001
Bipolar disorder 505 (1.1) 365 (1.2) 140 (1.1) 0.290
Schizophrenia 363 (0.8) 227 (0.7) 136 (1.0) 0.002
ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease.
Table 3. Proportion of patients with CKD receiving monitoring and medications by diabetes status.
Total n =
44,259 n (%)
Diabetes
p ValueNo n = 30,996
n (%)
Yes n = 13,263
n (%)
Blood Pressure
Patients with BP Recorded 39,716 (89.7) 27,411 (88.4) 12,305 (92.8) <0.001
Low Diastolic BP (<70 mmHg) 13,602 (34.2) 8935 (32.6) 4667 (37.9) <0.001
High Systolic BP (>140 mmHg) 13,338 (33.6) 9108 (33.2) 4230 (34.4) 0.033
Pathology
Patients with phosphate test
recorded 23,133 (52.3) 16,060 (51.8) 7073 (53.3) 0.004
Elevated phosphate level (>1.49
mmol/L) 1322 (5.7) 872 (5.4) 450 (6.4) 0.005
Patients with calcium test
recorded 22,818 (51.6) 16,096 (51.9) 6722 (50.7) 0.017
Elevated calcium level (>2.54
mmol/L) 1343 (5.9) 893 (5.5) 450 (6.7) <0.001
Low calcium level (<2.10 mmol/L) 589 (2.6) 409 (2.5) 180 (2.7) 0.584
Patients with Hb test recorded 40,601 (91.7) 28,723 (92.7) 11,878 (89.6) <0.001
Low Hb level (<7.5 mmol/L) 14,125 (34.8) 9252 (32.2) 4873 (41.0) <0.001
Medication
Antihypertensives
At least one antihypertensives , 32,782 (74.1) 21,893 (70.6) 10,889 (82.1) <0.001
Diuretic 9539 (21.6) 5956 (19.2) 3583 (27.0) <0.001
Beta Blocker 10,763 (24.3) 6862 (22.1) 3901 (29.4) <0.001
Calcium Channel Blocker 9551 (21.6) 6232 (20.1) 3319 (25.0) <0.001
ACEI or ARB 24,485 (55.3) 15,978 (51.5) 8507 (64.1) <0.001
Multiple ACEI or ARB 1859 (4.2) 1066 (3.4) 793 (6.0) <0.001
Statin 20,411 (46.1) 12,370 (39.9) 8041 (60.6) <0.001
All phosphate binders 244 (0.6) 155 (0.5) 89 (0.7) 0.031
Non-calcium-containing
phosphate binders 67 (0.2) 41 (0.1) 26 (0.2) 0.148
Calcium-containing phosphate
binders 182 (0.4) 119 (0.4) 63 (0.5) 0.197
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Table 3. Cont.
Total n =
44,259 n (%)
Diabetes
p ValueNo n = 30,996
n (%)
Yes n = 13,263
n (%)
Vitamin D 1444 (3.3) 939 (3.0) 505 (3.8) <0.001
ESAs 42 (0.1) 24 (0.1) 18 (0.1) 0.098
NSAIDs 7426 (16.8) 4862 (15.7) 2564 (19.3) <0.001
Metformin 5189 (11.7) 59 * (0.2) 5130 (38.7) <0.001
Digoxin 1516 (3.4) 976 (3.1) 540 (4.1) <0.001
BP, blood pressure; Hb, haemoglobin; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; ESAs, erythropoiesis-stimulating agents; NSAIDs, non-steroidal anti-inflammatory drugs. , Includes all
antihypertensives with anatomical therapeutic chemical (ATC) code C02, C03, C07, C08, C09, or combinations (as in
C10BX). * Patients with a prescription for metformin who did not have a recorded diagnosis of type 2 diabetes.
3.2. Appropriate Prescribing
Among patients with CKD stages 4–5 and hypertension, 79.9% overall and 83.5% of those aged
≥65 years were prescribed antihypertensive agents. The proportion of patients with microalbuminuria
(ACR 2.5–25 mg/mmol for males, 3.5–35 mg/mmol for females) and diabetes who were prescribed an
ACEI/ARB or an ACEI/ARB plus a diuretic were 69.9% and 20.6%, respectively. Overall, the prescribing
of ACEI/ARB in patients with macroalbuminuria (ACR > 25 mg/mmol for males, >35 mg/mmol for
females) was 62.3%. This was significantly higher in those patients aged ≥65 years than those < 65
years (65.4% vs. 56.1%, p < 0.001) and in those without documented CKD diagnosis (64.5% vs. 60.0%,
p = 0.046) than those documented. The proportion of patients with macroalbuminuria who were
prescribed an ACEI/ARB plus a diuretic was 20.4%, overall, and was significantly higher in those aged
≥65 years (22% vs. 16.7%, p = 0.021) than those <65 years (Table 4 and Supplementary Figure S1).
We examined the prescribing of statins in CKD patients with diabetes and in those aged between
50 and 65 years, as guidelines recommend statin use in both of these groups [12]. The proportion of
patients who were prescribed a statin was 39.9% in patients without diabetes and 60.6% in patients
with diabetes. The percentage of statin prescribing was 40.8% in patients with CKD aged between 50
and 65 years. Prescribing of statins in this age group was more common in patients with a SEIFA score
≤3 than >3 (45.3% vs. 38.9%, p < 0.001) and in patients with a documented CKD diagnosis (45.1% vs.
38.9%, p < 0.001) (Table 4 and Supplementary Figure S1).
3.3. Potentially Inappropriate Prescribing
The percentage of patients with potentially inappropriate prescribing of an NSAID in combination
with a RAS blocker and a diuretic (triple therapy) was 2.6%, overall. It was higher in those whose CKD
diagnosis was documented (3.0% vs. 2.5%, p = 0.002) than not documented, and in those aged ≥65
years (2.7% vs. 2.0%, p = 0.004) than aged <65 years. It was slightly higher in patients with SEIFA
score ≤3 than >3 (3.2% vs. 2.4%, p < 0.001) and in CKD patients living in regional and remote areas
than in patients living in major cities (2.8% vs. 2.5%; p = 0.032) (Table 4 and Supplementary Figure
S2). Among patients with eGFR < 30 mL/min/1.73 m2, the proportion prescribed an NSAID was 14.3%
overall and was higher in patients aged ≥65 years (15.1 vs. 9.4%, p < 0.001) than those aged <65 years
and in patients with SEIFA score ≤3 (15.9% vs. 13.6%, p = 0.033) than those with SEIFA score >3.
Of those patients with CKD stages 3–5 and prescribed a RAS blocker, 7.6% were prescribed at
least two RAS blockers simultaneously. This was more likely in patients with SEIFA score ≤3 than >3
(8.3% vs. 7.3%; p = 0.005) and in patients living in major cities than those living in regional and remote
areas (8.0% vs. 7.0%; p = 0.002) (Table 4 and Supplementary Figure S2).
There were 5130 patients with diabetes who were prescribed metformin. Of 1967 patients
with a diagnosis of diabetes and with an eGFR < 30 mL/min/1.73 m2, 278 (14.1%) were potentially
inappropriately prescribed metformin. This was slightly greater in patients living in regional and
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remote Australia (16.8%) than those living in major cities (12.3%; p = 0.005) and in patients whose CKD
diagnosis was not documented (16.3% vs. 12.5%; p = 0.018) (Table 4, Supplementary Figure S2).
In patients with an eGFR < 50 mL/min/1.73 m2, the proportion prescribed high-dose digoxin
(0.125 mg/day) was 3.8%. This was higher in females (4.1% vs. 3.3%, p < 0.001), in those aged ≥65
years (4.0% vs. 1.1%, p < 0.001) than aged <65 years, and in those living in regional and remote areas
(4.2% vs. 3.5%, p = 0.002) than those living in major cities (Table 4 and Supplementary Figure S2).
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Table 4. Number and proportion of patients meeting prescribing quality indicators by rurality, socio-economic indexes for areas (SEIFA) and CKD documentation [4].
Quality Indicator Numerator Denominator Percentage p Value
Treatment of Hypertension
1. Percentage of
patients aged 18 to 80
years with CKD
stages 4–5 and
hypertension who are
prescribed
antihypertensives
unless undesirable
because of low
diastolic blood
pressure
Overall * 1029 1288 79.9
Rurality
Major cities of
Australia 532 672 79.2 0.565
Regional and Remote
Australia 490 609 80.5
SEIFA quintile ≤3 345 433 79.7 0.947
>3 677 848 79.8
CoC
High 375 459 81.7 0.228
Low 654 829 78.9
CKD documented
No 380 485 78.4 0.284
Yes 649 803 80.8
Systolic BP >140 mmHg 455 573 79.4 0.541≤140 mmHg 588 728 80.8
Age <65 years 318 437 72.8 <0.001≥65 years 711 851 83.5
Sex
Female 450 561 80.2 0.800
Male 579 727 79.6
2. Percentage of
patients aged 18 to
80 years with CKD
stages 3–5 and
macroalbuminuria
treated with multiple
antihypertensives
who are prescribed a
combination of an
ACEI or ARB and a
diuretic
Overall * 298 1464 20.4
Rurality
Major cities of
Australia 174 837 20.8 0.679
Regional and Remote
Australia 123 618 19.9
SEIFA quintile ≤3 94 496 19.0 0.315
>3 203 958 21.2
CoC
High 104 528 19.7 0.639
Low 194 936 20.7
CKD documented
No 148 751 19.7 0.527
Yes 150 713 21.0
Systolic BP >140 mmHg 143 643 22.2 0.123≤140 mmHg 150 792 19.0
Age <65 years 74 444 16.7 0.021≥65 years 224 1020 22
Sex
Female 102 468 21.8 0.348
Male 196 996 19.7
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Table 4. Cont.
Quality Indicator Numerator Denominator Percentage p Value
3. Percentage of
patients aged 18 to 80
years with CKD
stages 3–5,
microalbuminuria
and diabetes treated
with multiple
antihypertensives
who are prescribed a
combination of an
ACEI or ARB and a
diuretic
Overall * 337 1634 20.6
Rurality
Major cities of
Australia 190 956 19.9 0.270
Regional and Remote
Australia 147 664 22.1
SEIFA quintile ≤3 110 513 21.4 0.672
>3 227 1106 20.5
CoC
High 144 641 22.5 0.140
Low 193 993 19.4
CKD documented
No 216 1075 20.1 0.462
Yes 121 556 21.8
Systolic BP >140 mmHg 119 563 21.1 0.667≤140 mmHg 213 1053 20.2
Age <65 years 40 228 17.5 0.215≥65 years 297 1406 21.1
Sex
Female 149 655 22.7 0.083
Male 188 979 19.2
Treatment of
albuminuria
4. Percentage of
patients aged 18 to
80 years with CKD
stages 3–5 and
macroalbuminuria
who are prescribed an
ACEI or ARB
Overall * 1084 1741 62.3
Rurality
Major cities of
Australia 636 1016 62.6 0.725
Regional and Remote
Australia 441 714 61.8
SEIFA quintile ≤3 353 573 61.6 0.705
>3 723 1156 62.5
CoC
High 387 645 60.0 0.135
Low 697 1096 63.6
CKD documented
No 578 898 64.5 0.046
Yes 506 845 60.0
Age <65 years 331 590 56.1 <0.001≥65 years 753 1151 65.4
Sex
Female 327 544 60.1 0.212
Male 757 1197 63.2
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Table 4. Cont.
Quality Indicator Numerator Denominator Percentage p Value
5. Percentage of
patients aged 18 to 80
years with CKD
stages 3–5,
microalbuminuria
and diabetes who are
prescribed an ACEI or
ARB
Overall * 1252 1790 69.9
Rurality
Major cities of
Australia 738 1064 69.4 0.516
Regional and Remote
Australia 502 709 70.8
SEIFA quintile ≤3 393 546 72.0 0.207
>3 846 1226 69.0
CoC
High 502 705 71.2 0.348
Low 750 1085 69.1
CKD documented
No 841 1179 71.3 0.075
Yes 411 611 67.3
Age <65 years 176 259 68 0.450≥65 years 1076 1531 70.3
Sex
Female 496 711 69.8 0.891
Male 759 1079 70.1
Prescription of statins
6. Percentage of
patients aged 50 to
65 years with CKD
stages 3–5 who are
prescribed a statin
Overall * 1508 3693 40.8
Rurality
Major cities of
Australia 823 2023 40.7 0.898
Regional and Remote
Australia 669 1636 40.9
SEIFA quintile ≤3 488 1077 45.3 <0.001
>3 1004 2581 38.9
CoC
High 542 1292 42.0 0.311
Low 966 2401 40.2
CKD documented
No 991 2547 38.9 <0.001
Yes 517 1146 45.1
Sex
Female 714 1814 39.4 0.073
Male 794 1879 42.3
Treatment of MBD
7. Percentage of patients aged 18 to 80 years with CKD stages 3–5 and
with an elevated phosphate level who are prescribed a phosphate binder 54 815 6.6
8. Percentage of patients aged 18 to 80 years with CKD stages 3–5
treated with phosphate binders and with an elevated calcium level who
are prescribed a non-calcium-containing phosphate binder
5 7 71.4
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Table 4. Cont.
Quality Indicator Numerator Denominator Percentage p Value
9. Percentage of patients aged 18 to 80 years with CKD stages 3–5
treated with phosphate binders and with a low calcium level who are
prescribed a calcium-containing phosphate binder
6 12 50.0
Medication safety
10. Percentage of
patients 18 years or
older with CKD
stages 3–5 and a
prescription of RAS
blockers who are
prescribed at least
two RAS blockers
simultaneously
Overall * 1859 24,485 7.6
Rurality
Major cities of
Australia 1175 14,639 8.0 0.002
Regional and Remote
Australia 678 9732 7.0
SEIFA quintile ≤3 587 7037 8.3 0.005
>3 1264 17,317 7.3
CoC
High 727 9756 7.5 0.499
Low 1132 14,729 7.7
CKD documented
No 1339 18,073 7.4 0.069
Yes 520 6412 8.1
Age <65 years 182 2076 8.8 0.035≥65 years 1677 22,409 7.5
Sex
Female 1007 13,466 7.5 0.455
Male 852 11,019 7.7
11. Percentage of patients 18 years or older with CKD stages 3–5 and
elevated calcium levels who are prescribed active vitamin D 67 1343 5.0
12. Percentage of patients 18 years or older with CKD stages 3–5 and
Hb ≥ 7.5 who are prescribed ESA 0 26,476 0.0
13. Percentage of
patients 18 years or
older with Egfr
< 30 mL/min/1.73 m2
who are prescribed a
NSAID
Overall * 735 5146 14.3
Rurality
Major cities of
Australia 421 3054 13.8 0.201
Regional and Remote
Australia 312 2072 15.1
SEIFA quintile ≤3 238 1496 15.9 0.033
>3 494 3627 13.6
CoC
High 295 2058 14.3 0.935
Low 440 3087 14.3
CKD documented
No 352 2367 14.9 0.266
Yes 383 2779 13.8
Age <65 years 68 724 9.4 <0.001≥65 years 667 4422 15.1
Sex
Female 360 2648 13.6 0.147
Male 375 2498 15.0
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Table 4. Cont.
Quality Indicator Numerator Denominator Percentage p Value
14. Percentage of
patients 18 years or
older with Egfr
< 30 mL/min/1.73 m2
and diabetes who are
prescribed metformin
Overall * 278 1967 14.1
Rurality
Major cities of
Australia 149 1208 12.3 0.005
Regional and Remote
Australia 126 749 16.8
SEIFA quintile ≤3 80 608 13.2 0.444
>3 195 1349 14.4
CoC
High 119 829 14.4 0.810
Low 159 1138 14.0
CKD documented
No 136 835 16.3 0.019
Yes 142 1132 12.5
Age <65 years 32 244 13.1 0.625≥65 years 246 1723 14.3
Sex
Female 127 957 13.3 0.285
Male 151 1010 15
15. Percentage of
patients 18 years or
older with eGFR
< 50 mL/min/1.73 m2
who are prescribed
digoxin
> 0.125 mg/day
Overall * 995 26,434 3.8
Rurality
Major cities of
Australia 558 16,020 3.5 0.002
Regional and Remote
Australia 433 10,282 4.2
SEIFA quintile ≤3 293 7394 4.0 0.295
>3 697 18,893 3.7
CoC
High 366 10,623 3.4 0.025
Low 629 15,807 4.0
CKD documented
No 696 17,547 4.0 0.015
Yes 299 8887 3.4
Age <65 years 25 2252 1.1 <0.001≥65 years 970 24,182 4.0
Sex
Female 596 14,411 4.1 <0.001
Male 399 12,023 3.3
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Quality Indicator Numerator Denominator Percentage p Value
16. Percentage of
patients 18 years or
older with CKD
stages 3–5 and who
are prescribed with a
combination of
NSAID, RAS blocker
and diuretic
Overall * 1160 44,259 2.6
Rurality
Major cities of
Australia 663 26,617 2.5 0.032
Regional and Remote
Australia 492 17,420 2.8
SEIFA quintile ≤3 397 12,254 3.2 <0.001
>3 757 31,758 2.4
CoC
High 452 17,421 2.6 0.777
Low 708 26,833 2.6
CKD documented
No 809 32,641 2.5 0.002
Yes 351 11,618 3.0
Age <65 years 86 4373 2.0 0.004≥65 years 1074 39,886 2.7
Sex
Female 640 24,165 2.6 0.691
Male 520 20,094 2.6
BP, blood pressure; CKD, chronic kidney disease; MBD, mineral and bone density; CoC, continuity of care; SEIFA, socio-economic indexes for areas; ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin receptor blocker; RAS, renin-angiotensin system; eGFR, estimated glomerular filtration rate; ESAs, erythropoiesis-stimulating agents; NSAIDs, non-steroidal
anti-inflammatory drugs. * ‘Patient SEIFA’, ‘Patient Rurality’, Patient CoC’, and ‘CKD documented’ for the indicator does not add up to ‘Overall’ due to missing data.
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4. Discussion
This study is the most extensive to date that evaluates the quality of medication prescribing in
Australian general practice patients with CKD, utilising a set of 16 validated indicators and based
on diabetes status [11]. Potential gaps in prescribing CKD progression protective medications and
avoiding nephrotoxic drugs were identified. ACEIs/ARBs in patients with proteinuria or diabetes
and statins in patients aged between 50 and 65 years were found to be under-prescribed. Potential
inappropriate prescribing identified included simultaneous prescribing of at least two RAS inhibitors,
prescribing of NSAIDs and metformin in patients with eGFR <30 mL/min/1.73 m2, and use of high-dose
digoxin in patients with an eGFR < 50 mL/min/1.73 m2. With at least one indicator, inappropriate
prescribing was more common in patients with SEIFA ≤ 3, aged ≥65 years, or living in regional and
remote Australia. Compared with patients without diabetes, patients with diabetes generally received
more comprehensive blood pressure and laboratory monitoring and pharmacotherapy.
Despite strong evidence for the efficacy of ACEI/ARB to reduce proteinuria and slow progression
of CKD to ESKD, less than 70% of Australian adult patients with CKD stages 3–5 with diabetes and
microalbuminuria were receiving an ACEI or ARB. The prescribing of an ACEI or ARB in patients with
CKD with albuminuria was slightly lower in Australian general practice compared to that reported
in other developed nations [24–27]. Studies from different provinces of Canada [24–26] investigating
prescribing in CKD patients reported rates of 74% to 80% for ACEI or ARB prescribing, while a study
conducted in the Netherlands found prescribing in 78% and 82% of non-diabetes and diabetes patients,
respectively [11]. The reason for the low rate of ACEI/ARB prescribing could be non-concordance to
Australian CKD treatment guidelines, including not referring patients to nephrology care [3]. The cost
of ACEI/ARB probably had a limited impact on the rate of their prescription as these medications are
subsidized by the Australian Pharmaceutical Benefits Scheme (PBS).
It was unexpected to find no difference or even low rates of an ACEI or ARB/an ACEI or ARB plus
diuretic prescribing in patients with proteinuria and documented CKD compared to those without
documented CKD. This might suggest that GPs awareness of patients’ CKD status did not necessarily
compel them to prescribe an ACEI/ARB. They may have other valid reasons for not prescribing,
including hyperkalemia, hypotension, and acute renal injury (AKI) [28]. Among CKD patients with
proteinuria who were receiving multiple antihypertensive agents, only a fifth use an ACEI/ARB in
combination with a diuretic (double therapy) in this study. Double and triple (ACEI/ARB plus a
diuretic plus an NSAID) therapies are associated with AKI [29], which might have discouraged GPs
from prescribing. However, compared with those with triple therapy, the risk of developing AKI
is less likely in patients with double therapy [29]. Combining ACEI/ARB with a thiazide diuretic
instead of a loop diuretic might reduce the risk of discontinuation of ACEI/ARB [30]. The risk of
inducing hypotension and the associated fall in elderly patients might outweigh the renoprotective
effect gained by combining an ACEI/ARB with a diuretic, and it might have also prevented GPs from
prescribing [30,31].
Statins are relatively well-tolerated medications and are beneficial in lowering the risk of
cardiovascular events in patients with CKD [12,32]. Notwithstanding the PBS restrictions on the
prescribing of statins, the current Kidney Disease: Improving Global Outcomes (KDIGO) and Kidney
Health Australia’s guidelines [3,12] recommend statin or statin/ezetimibe treatment in adults aged
50 years and over with eGFR < 60 mL/min/1.73 m2 but not treated with chronic dialysis or kidney
transplantation. In this study, only 40.8% of patients aged 50 to 65 years were receiving statins. These
rates were less than a 54% lipid-lowering medication prescribing rate in primary care patients with CKD
reported by a prior Australian study, AusHEART [33]. A study by Smits et al. [11] in the Netherlands
using the same indicators reported a higher (74%) rate of statin prescribing in patients with CKD
stages 3–5 aged 50 to 65 years. The significantly low rate of statin prescribing in those patients without
documented CKD diagnosis (38.9%) suggests that lack of CKD recognition by GPs might be one reason
for the low rate of statin prescribing.
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Statin side effects and interactions were the main concerns of Australian patients taking statin [34],
and which were also cited as the most commons reasons for statin discontinuation elsewhere [35].
The low rate of statin therapy in this study could be related to public concern over perceived adverse
reactions following an extensive media campaign about the negative effect of statins [36]. The other
likely reason is the lack of PBS subsidisation for statin therapy for CKD in the absence of other
indications [37].
Our study indicated that patients living in relatively disadvantaged socio-economic areas (SEIFA
score ≤ 3) were more likely to be prescribed potentially inappropriate NSAIDs, simultaneous use
of at least two RAS inhibitors, and triple therapy (combined use of an NSAID, a RAS inhibitor and
a diuretic). Similarly, patients from regional or remote areas of Australia were more likely to be
prescribed potentially inappropriate digoxin, metformin, and triple therapy. These findings suggest
that patients living in disadvantaged socio-economic areas, as well as regional and remote areas, may
receive a lower quality of CKD care than patients living in socio-economic most advantaged areas or
major cities. The health care inequality between regional/remote areas and major cities of Australia
has been the subject of many reports and initiatives [38]. Three in five people in remote/very remote
areas did not see a specialist because of distance, and people in outer regional and remote/very remote
areas were less likely to have a usual GP [38]. Inequality in prescribing has also been found elsewhere.
A study in France [39] reported that inappropriate prescribing was highest in older people living in
municipalities with low socio-economic status. A similar study conducted in Ireland [40] also found
that inappropriate prescribing was more prevalent in relatively deprived patients aged over 70 years.
In this study, patients with CKD and aged 65 years or over were more likely to be prescribed
nephrotoxic medications: triple therapy, high-dose digoxin, and NSAIDs. One possible explanation is
that some GPs may not consider an eGFR measurement between 45–59 mL/min/1.73 m2 as evidence of
CKD in older individuals. They might consider these eGFR values as reflecting the normal physiological
changes related to aging.
Unlike a previous study by Khanam et al. [31], using MedicineInsight data, which found higher
CoC led to better blood pressure control, this study found no significant differences in prescribing
quality between patients with higher and lower CoC.
5. Strengths and Limitations
This study had a large sample size, and patient characteristics within the MedicineInsight dataset
are similar to the Australian population [2,14,16]. However, there are several limitations. Medications
prescribed solely by specialists, such as nephrologists and cardiologists, who worked in hospitals and
speciality clinics were not recorded in NPS MedicineWise MedicineInsight. For instance, phosphate
binders and ESAs are not usually prescribed by GPs (generally prescribed by nephrologists), and thus
our data were not complete on the use of these medications.
We did not account for medication contraindications and adverse drug reactions that may have
prevented GPs from prescribing a specific class of medication to patients. Adverse drug reactions are
recorded in free text in ‘Allergies/Reactions Table’ in the NPS MedicineWise MedicineInsight dataset.
This table is not an event-based table and does not necessarily record each occurrence of adverse drug
reaction. Free-text search for an adverse drug reaction from this table is of poor quality.
NSAIDs are also available without a prescription, but we could only obtain data on prescribed
NSAIDs. Simultaneous prescribing of at least two RAS blockers within the four months might not
necessarily indicate concomitant inappropriate use. It might be an overlapping period of switching
from one RAS blocker monotherapy to the other. We also did not investigate the impact of medication
use on patient outcomes.
GPs collected the data for clinical decision making, not for research purposes. The EHRs may
not contain all sociodemographic and clinical characteristics. For instance, indigenous status was
not recorded for 24.3% of the patients. There is a possibility that aspects of patients’ medical history,
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prescriptions, and laboratory tests were recorded in notes and not included in the research data, which
used specified fields and not the body of free-text consultation notes.
We noted that including only regular patients (who had three or more clinical encounters in past
two years) in this study potentially introduced selection bias by including more older patients with
multiple comorbidities who visited their GP more frequently. However, four in five Australian patients
visited their GP multiple times in a year [41], and nearly all patients could visit their GP at least
three times in two years. In conclusion, we identified the potential for possible improvement in the
prescribing of recommended preventive medications and deprescribing of nephrotoxic medication in
patients with CKD in Australian primary care. Programmes to optimise the quality use of medications
should focus on improving the prescribing practices for protective medications, such as an ACEI or
ARB and a statin, and deprescribing concurrent NSAIDs and RAS blockers in patients with CKD.
Supplementary Materials: The data we used for this study is stored only in Australia and can be obtained from
MedicineInsight. The following are available online at http://www.mdpi.com/2077-0383/9/3/783/s1, Figure S1:
Appropriate prescribing in patients with chronic kidney disease (CKD) stages 3-5 assessed with prescribing quality
indicators (PQIs), Figure S2: Potential inappropriate prescribing assessed with five prescribing quality indicators
(PQIs).
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ACEIs angiotensin-converting enzyme inhibitors
ACR albumin-to-creatinine ratio
AKI acute kidney injury
ARBs angiotensin receptor blockers
ATC anatomical therapeutic chemical
CKD chronic kidney disease
CoC continuity of care
EHRs electronic health records
eGFR estimated glomerular filtration rate
ESAs erythropoiesis-stimulating agents
GPs general practitioners
KDIGO Kidney Disease: Improving Global Outcomes
NSAIDs non-steroidal anti-inflammatory drugs
PQIs prescribing quality indicators
RAS renin-angiotensin system
SEIFA socio-economic indexes for areas
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